Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil

The present study aimed to evaluate the effectiveness of two doses of CoronaVac in preventing SARS-CoV-2 symptomatic disease with virological confirmation, as well as in the prevention of COVID-19 moderate and severe cases. A test-negative unmatched case-control design was used, in which cases were...

Full description

Saved in:
Bibliographic Details
Main Authors: Expedito J.A. Luna, José C. Moraes, Manuela A. Roediger, Erique J.F.P. Miranda, Patrícia E. Braga, João I.D. França, Pedro H.M. Pacheco, Marcos Alves de Lima, Lucas Ragiotto, Eliana N.C. Barros
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Brazilian Journal of Infectious Diseases
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1413867024001399
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850203074545582080
author Expedito J.A. Luna
José C. Moraes
Manuela A. Roediger
Erique J.F.P. Miranda
Patrícia E. Braga
João I.D. França
Pedro H.M. Pacheco
Marcos Alves de Lima
Lucas Ragiotto
Eliana N.C. Barros
author_facet Expedito J.A. Luna
José C. Moraes
Manuela A. Roediger
Erique J.F.P. Miranda
Patrícia E. Braga
João I.D. França
Pedro H.M. Pacheco
Marcos Alves de Lima
Lucas Ragiotto
Eliana N.C. Barros
author_sort Expedito J.A. Luna
collection DOAJ
description The present study aimed to evaluate the effectiveness of two doses of CoronaVac in preventing SARS-CoV-2 symptomatic disease with virological confirmation, as well as in the prevention of COVID-19 moderate and severe cases. A test-negative unmatched case-control design was used, in which cases were patients with suspected COVID-19 (presenting at least two of the following symptoms: fever, chills, sore throat, headache, cough, runny nose, olfactory or taste disorders) with virological confirmation, and controls were those whose SARS-CoV-2 test was negative. As for exposure, participants were classified as unvaccinated, or vaccinated with a complete schedule. Suspected COVID-19 cases were identified from March to November 2021, in two cities located in the State of São Paulo, Brazil. All participants signed the Informed Consent Form before enrollment. RT-PCR results and vaccination data were obtained from the local surveillance systems. Up to two phone calls were made to obtain information on the outcome of the cases. A total of 2981 potential participants were screened for eligibility, of which 2163 were included, being 493 cases and 1670 controls. Vaccination, age, the reported contact with a COVID-19 suspected or confirmed case in the 14 days before symptoms onset, and the educational level were the variables independently associated with the outcome. The adjusted vaccine effectiveness for symptomatic COVID-19 (AVE) was 39.0 % (95 % CI 6.0–60.0 %). The AVE in the prevention of moderate and severe disease was 91.0 % (95 % CI 76.0–97.0 %). Our results were influenced by the waning of the Gamma variant, in the second trimester of 2021, followed by the increase in vaccination coverage, and a drop in the number of cases in the second half of the year. The study demonstrated the high effectiveness of CoronaVac in preventing moderate/severe COVID-19 cases.
format Article
id doaj-art-51dde490bde84c0f90745b91df4b8e65
institution OA Journals
issn 1413-8670
language English
publishDate 2024-09-01
publisher Elsevier
record_format Article
series Brazilian Journal of Infectious Diseases
spelling doaj-art-51dde490bde84c0f90745b91df4b8e652025-08-20T02:11:37ZengElsevierBrazilian Journal of Infectious Diseases1413-86702024-09-0128510385610.1016/j.bjid.2024.103856Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in BrazilExpedito J.A. Luna0José C. Moraes1Manuela A. Roediger2Erique J.F.P. Miranda3Patrícia E. Braga4João I.D. França5Pedro H.M. Pacheco6Marcos Alves de Lima7Lucas Ragiotto8Eliana N.C. Barros9Universidade de São Paulo, Faculdade de Medicina, São Paulo, SP, Brazil; Corresponding author.Faculdade de Ciências Médicas da Santa Casa, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilInstituto Butantan, São Paulo, SP, BrazilThe present study aimed to evaluate the effectiveness of two doses of CoronaVac in preventing SARS-CoV-2 symptomatic disease with virological confirmation, as well as in the prevention of COVID-19 moderate and severe cases. A test-negative unmatched case-control design was used, in which cases were patients with suspected COVID-19 (presenting at least two of the following symptoms: fever, chills, sore throat, headache, cough, runny nose, olfactory or taste disorders) with virological confirmation, and controls were those whose SARS-CoV-2 test was negative. As for exposure, participants were classified as unvaccinated, or vaccinated with a complete schedule. Suspected COVID-19 cases were identified from March to November 2021, in two cities located in the State of São Paulo, Brazil. All participants signed the Informed Consent Form before enrollment. RT-PCR results and vaccination data were obtained from the local surveillance systems. Up to two phone calls were made to obtain information on the outcome of the cases. A total of 2981 potential participants were screened for eligibility, of which 2163 were included, being 493 cases and 1670 controls. Vaccination, age, the reported contact with a COVID-19 suspected or confirmed case in the 14 days before symptoms onset, and the educational level were the variables independently associated with the outcome. The adjusted vaccine effectiveness for symptomatic COVID-19 (AVE) was 39.0 % (95 % CI 6.0–60.0 %). The AVE in the prevention of moderate and severe disease was 91.0 % (95 % CI 76.0–97.0 %). Our results were influenced by the waning of the Gamma variant, in the second trimester of 2021, followed by the increase in vaccination coverage, and a drop in the number of cases in the second half of the year. The study demonstrated the high effectiveness of CoronaVac in preventing moderate/severe COVID-19 cases.http://www.sciencedirect.com/science/article/pii/S1413867024001399SARS-CoV2Inactivated vaccinesEffectivenessTest-negativeCase-control studyBrazil
spellingShingle Expedito J.A. Luna
José C. Moraes
Manuela A. Roediger
Erique J.F.P. Miranda
Patrícia E. Braga
João I.D. França
Pedro H.M. Pacheco
Marcos Alves de Lima
Lucas Ragiotto
Eliana N.C. Barros
Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil
Brazilian Journal of Infectious Diseases
SARS-CoV2
Inactivated vaccines
Effectiveness
Test-negative
Case-control study
Brazil
title Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil
title_full Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil
title_fullStr Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil
title_full_unstemmed Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil
title_short Effectiveness of CoronaVac in the prevention of COVID-19, a test-negative case-control study in Brazil
title_sort effectiveness of coronavac in the prevention of covid 19 a test negative case control study in brazil
topic SARS-CoV2
Inactivated vaccines
Effectiveness
Test-negative
Case-control study
Brazil
url http://www.sciencedirect.com/science/article/pii/S1413867024001399
work_keys_str_mv AT expeditojaluna effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT josecmoraes effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT manuelaaroediger effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT eriquejfpmiranda effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT patriciaebraga effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT joaoidfranca effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT pedrohmpacheco effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT marcosalvesdelima effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT lucasragiotto effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil
AT elianancbarros effectivenessofcoronavacinthepreventionofcovid19atestnegativecasecontrolstudyinbrazil